rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Burning Rock Biotech Limited - American Depositary Shares

BNR · Nasdaq

Health CareDiagnostics & LabsNot moving yet

BNR stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 25 weeks. It is 2.5% below that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 25
Industry in uptrend
48% -2 in 4 wk
Insider buys, 12 months
$23.3M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
17 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

17 Apr – 16 Oct
20%38%55%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$11.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Yusheng HanDirectorbought24,900at $8.0026 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought250,000at $8.0024 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought5,990at $7.5023 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought104,650at $7.4522 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought111,110at $9.0016 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought210,000at $9.2512 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought24,760at $8.7411 Jun 2026filed 2 Jul 2026
Yusheng HanDirectorbought314,870at $17.3631 Mar 2026filed 2 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders17+2 on the quarter
New · exited4 · 2
Reported value$14.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Kynam Capital Management, LPadded · filed 14 Aug 20261,238,563$10.5M+11,008+0.9%
CRCM LPreduced · filed 12 Aug 2026211,997$1.8M-70,100−24.8%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 202652,838$442K+17,431+49.2%
MORGAN STANLEYadded · filed 13 Aug 202643,594$365K+28,322+185.5%
Sumitomo Mitsui Trust Group, Inc.reduced · filed 30 Jul 202629,724$249K-413−1.4%
Amova Asset Management Americas, Inc.reduced · filed 13 Aug 202629,724$258K-413−1.4%
BANK OF AMERICA CORPunchanged · filed 14 Aug 202629,164$244K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202627,288$237K+9,619+54.4%
HSG Holding Ltdunchanged · filed 13 Aug 202621,212$178K00.0%
UBS Group AGadded · filed 13 Aug 202617,916$150K+17,508+4291.2%
31 Mar 2023 – 30 Jun 2026
162329Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Yusheng Han Company insiderDirector · last 26 Jun 20268 · 0

Same industry

TRIB Trinity BiotechLeading+97%
CDNA CareDxLeading+83%
XGN ExagenLeading+49%
NTRA NateraLeading+46%
FTRE Fortrea HoldingsLeading+41%
PSNL PersonalisLeading+35%
TKNO Alpha TeknovaLeading+32%
ADPT Adaptive BiotechnologiesLeading+20%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202574.7%
Operating profit marginFY 2025 · to 31 Dec 2025-10.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-37.8%
Return on capital employedFY 2025 · to 31 Dec 2025-9.6%
Research spendFY 2025 · to 31 Dec 202530.9%
Revenue growthFY 2025 · to 31 Dec 20259.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$478.4M
Free cash flowFY 2025 · to 31 Dec 2025−$29.2M

Analyst forecasts

No analyst forecasts yet.